[{"orgOrder":0,"company":"Tikomed","sponsor":"IQVIA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TIKOMED and IQVIA Announce a Strategic Collaboration for The Development of TIKOMED's Lead Drug Platform Candidate ILB","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Tikomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tikomed's Ilb\u00ae Mobilizes and Modulates Key Growth Factors That Trigger a Cascade of Neuroprotective Mechanisms Able to Target All Neuroinflammation-driven Diseases Including ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals for ILB
These studies show that ILB® releases, re-distributes and modulates the bioactivity of endogeneous heparin-binding growth factors that target disease compromised nervous tissues to initiate a cascade of transcriptional, metabolic and immunological effects.
The collaboration will support TikoMed's lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative potential and clinical development, regulatory and commercial strategies.